Britian has jumped the gun on gene editing
By Donna Dickenson,
Telegraph [UK]
| 02. 02. 2016
Untitled Document
For the first time Britain’s Human Fertilisation and Embryology Authority (HFEA) has granted researchers permission to use a new “gene editing” technique called Crispr/Cas9 to modify human embryos. This is despite a global summit held last December by the National Academies of Science in Washington which warned that, when it comes to this powerful new technique, no nation should go it alone. Other countries such as the United States are just as advanced as Britain in gene editing – indeed, the techniques authorised by HFEA were partly developed in America. But these nations are, rightly, being more cautious in using it.
Why? Their objections do not rest on religion or Luddite opposition to new technology. And it is not gene editing per se – they have fewer concerns about the technique’s use to correct genetic problems in individual living patients. But around the world, expert scientists and bioethicists are worried about its use to modify human embryos. If such embryos are reimplanted in the womb and born, genetic modifications would not be confined to them, but passed down...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...